Since several inhibitors targeting KRAS oncoproteins carrying the G12C mutation have reached the clinic [37, 38, 39], our model (Fig. S6) raises a note of caution that high KSR expression levels may decrease tumour sensitivity to these as well as to forthcoming KRAS inhibitors. The gene discussed is KRAS; the disease is neoplasm.